TOXICOLOGICAL PROFILE FOR STYRENE

Agency for Toxic Substances and Disease Registry U.S. Public Health Service

September 1992

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

FOREWORD

The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) extended and amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances which are most commonly found at facilities on the CERCLA National Priorities List and which pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The lists of the 250 most significant hazardous substances were published in the Federal Register on April 17, 1987; on October 20, 1988; on October 26, 1989; and on October 17, 1990. A revised list of 275 substances was published on October 17, 1991.

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the lists. Each profile must include the following content:

- (A) An examination, summary, and interpretation of available toxicological information and epidemiological evaluations on the hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure which present a significant risk to human health of acute, subacute, and chronic health effects.
- (C) Where appropriate, an identification of toxicological testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the <u>Federal Register</u> on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile is intended to characterize succinctly the toxicological and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. Other pertinent literature is also presented but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Foreword

Each toxicological profile begins with a public health statement, which describes in nontechnical language a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health will be identified by ATSDR, the National Toxicology Program (NTP) of the Public Health Service, and EPA. The focus of the profiles is on health and toxicological information; therefore, we have included this information in the beginning of the document.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

This profile reflects our assessment of all relevant toxicological testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control, the NTP, and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

William L. Roper, M.D., M.P.H.

William L. Roper

Administrator Agency for Toxic Substances and

Disease Registry

CONTENTS

FORE	EWORI		. • • • •					•	•			•										iii
LIST	OF	FIGURES																	٠			ix
LIST	OF	TABLES									•							•		•	•	xi
1.	PUBI		TH STATE																			1
	1.1	I TAHW	S STYREN	Ε?																		1
	1.2	HOW MI	GHT I BE	EXPOS	ED TO) STY	YREN	E?														2
	1.3		N STYREN																			1 2 2 2
	1.4	HOW CA	N STYREN	E AFFE	CT MY	HEA	ALTH	?														2
	1.5	IS THE	RE A MED	CAL T	രാന സ	יח חי	וממידים	MTNT	T T	יכון וד	דו ויד	חי	т :		77	DE:	TAS					
		EXPOSE	D TO STY	RENE?	 ESI I																	3
	1.6	WHAT R	ECOMMENDA	ATIONS																		
		TO PRO	TECT HUMA	AN HEA	LTH?											_						4
	1.7	WHERE	CAN T GET	MORE	INFO	RMAT	TON	?			•		•	•	·	•	•	•	•	•	•	4
		***************************************	0.11. 1 02.		11,1			•	•	•	•	•	•	• •	•	•	•	•	•	•	•	7
2.	нгат	TH EFFE	' ር ፕሮ																			5
۷.	2.1		TICTTON					•	•	•	•	•	•		•	•	•	•	•	•	•	5
	2.1	DISCUS	UCTION . SION OF 1		· ·	···	D37		י י		•				•	•	٠	•	•	•	•	
	2.2	DISCOS	SION OF F	ILALIH	EFFE	.015	BY .	ROU	ΙĿ	OF	ŁX	.PO	SU	KE	•	٠	٠	٠	•	•	•	5
		2.2.1		on Exp	posur	e .		•		•	•	•	•		•	•	•	•	•	•	•	6
			2.2.1.1	Death	ì.			•			•	•	•		•	•	٠	•	•	•	•	6
			2.2.1.2		emic	Effe	ects									•	•	•	•			6
			2.2.1.3	Immur	nolog	ical	Ef:	fect	ts													18
			2.2.1.4		ologi	cal	Eff	ect	s.													19
			2.2.1.5	Deve]	lopme	ntal	Ef:	fect	ts													21
			2.2.1.6	Repro	duct	ive	Effe	ect	s.													22
			2.2.1.7	Genot																		23
			2.2.1.8	Cance																		24
		2.2.2	Oral Exp																			26
		2.2.2	2.2.2.1																			26
			2.2.2.2																			
																						27
			2.2.2.3	Immur																		35
			2.2.2.4	Neuro	progr	cai	EII	ect	5.	•	•	•	•		•	•	٠	•	•	•	•	35
			2.2.2.5	Deve]	Lopme	ntal	Ef:	tect	ts	•	•	•	•		•	•	•	•	•	•	•	36
			2.2.2.6	Repro	oduct	ive	Effe	ects	3.	•						•						36
			2.2.2.7	Genot	coxic	Eff	ect	S														36
			2.2.2.8	Cance	er.			•														37
		2.2.3	Dermal E	xposui	ce :																	38
			2.2.3.1	Death	ı.																	38
			2.2.3.2	Syste																		38
			2.2.3.3	Immur																		40
			2.2.3.4	Neuro																		40
			2.2.3.5	Devel																		40
			2.2.3.6	Repro																		40
			2.2.3.7	Genot																		40
	2 2	TOVIAC	2.2.3.8	Cance																		40
	2.3		KINETICS																			40
		2.3.1	Absorpti	on .																		40

			2.3.1.1	Inhalatio	n Expo	sure			•		•		•	•	•	•	•	•	40
			2.3.1.2	Oral Expo															41
•			2.3.1.3	Dermal Ex	posure						•			•		•			41
		2.3.2	Distribut	cion															41
			2.3.2.1	Inhalatio	n Expo	sure													41
			2.3.2.2	Oral Expo															42
			2.3.2.3	Dermal Ex	posure														42
		2.3.3		sm															43
		2.3.4	Excretion	n					_		-						٠.		45
		2.3.	2 3 4 1	Inhalatio	n Expo	sure								i				•	45
			2.3.4.2	Oral Expo	cure	Jul		•	•	• •	•	• •	•	•	•	•	•	•	46
			2.3.4.2	Dermal Ex	DOCUTA	• •	•	• •	•	• •	•	• •	•	•	•	•	•	•	46
	2 /	מעט דעט	ע.ט.ט.ט אור אר אווו	BLIC HEALT	.posure	•	•	• •	•	• •	•	• •	•	•	•	•	•	•	46
				KPOSURE AN															55
	2.5			cs Used to))
		2.5.1																	55
		0 5 0	to Styrer	ne			· ·	 . E£	·			• •	٠.	•	•	•	•	•	رر
		2.5.2		cs Used to															57
			Styrene				•		•		•		•	•	•	•	•	•	
	2.6	INTERA	CTIONS WIT	TH OTHER C	HEMICA	LS	•	• •	·		•		•	•	•	•	•	•	57
	2.7			r are unus															58
	2.8			FFECTS .															58
	2.9			DATABASE															60
		2.9.1	Existing	Informati	on on	Heal	th	Eff	ect	s c	of :	Sty	rei	ne					60
		2.9.2	Data Need	ds															60
		2.9.3	On-going	Studies															66
3.	CHEM	ICAL AN	D PHYSICAL	L INFORMAT	CION .														69
	3.1	CHEMIC	AL IDENTI	гч															69
	3.2	PHYSIC	AL AND CHI	EMICAL PRO	PERTIE	S.	_												69
							•		-		-		-	-					
4.	PRODI	UCTION	IMPORT. I	USE, AND D	ISPOSA	L.	_		_					_					73
•	4.1																		73
	4.2																		73
																			73
																			76
	4.4	DISLOS	AL				•		•		•		•	•	•	•	•	•	/ 0
F	DOMES	ATTECT AT TO	OD HILIMAN I	EXPOSURE															77
5.																			
	5.1																		
	5.2			ENVIRONME															
		5.2.1																	77
		5.2.2																	81
		5.2.3					•				•			•		•		•	81
	5.3		NMENTAL FA																82
		5.3.1	Transport	t and Part	itioni	ng													82
		5.3.2	Transform	nation and	l Degra	dati	.on												83
			5.3.2.1	Air															83
			5.3.2.2	Water .															84
			5.3.2.3																84
	5.4	LEVELS		D OR ESTIM	IATED T	N TH	IE I	ENV	[RO	NME	NT								84
	~ . ¬	5.4.1																	84
		5.4.2																	85
		5.4.2																	85
		5.4.4		 vironmenta															85
		J.4.4	ACHET EIL	A TI OTHIGHTS	T LICOT	.a.,	•		•		•		•	•	•	•	•	•	0.

•

	5.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE									87
	5.6	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES									87
	5.7	ADEQUACY OF THE DATABASE									87
		5.7.1 Data Needs									87
		5.7.2 On-going Studies	•	٠	 •	•	•	•	•	•	90
6.	ANAL	YTICAL METHODS									. 91
	6.1	BIOLOGICAL MATERIALS									91
	6.2	ENVIRONMENTAL SAMPLES					٠				95
	6.3	ADEQUACY OF THE DATABASE									96
		6.3.1 Data Needs									96
		6.3.2 On-going Studies	•	•	 •	•	•	•	•	٠	98
7.	REGU	LATIONS AND ADVISORIES							·.	•	99
8.	REFE	RENCES									103
9.	GLOS	SARY								•	137
APP	ENDIC	ES									
	Α.	USER'S GUIDE							•		A-1
	В.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS							•		B-1
	G.	PEER REVIEW									C-1

LIST OF FIGURES

2-1	Levels of Significant Exposure to Styrene - Inhalation		٠	12
2-2	Levels of Significant Exposure to Styrene - Oral			32
2-3	Metabolic Pathways of Styrene			44
2-4	Existing Information on Health Effects of Styrene	• .•		61
5-1	Frequency of NPL Sites with Styrene Contamination			78

.

LIST OF TABLES

2-1	Levels of Significant Exposure to Styrene - Inhalation	7
2-2	Levels of Significant Exposure to Styrene - Oral	28
2-3	Levels of Significant Exposure to Styrene - Dermal	39
2-4	Genotoxicity of Styrene <u>In Vitro</u>	52
2-5	Genotoxicity of Styrene <u>In Vivo</u>	53
2-6	On-going Studies on Styrene	67
3-1	Chemical Identity of Styrene	70
3-2	Physical and Chemical Properties of Styrene	71
4-1	Facilities That Manufacture or Process Styrene	74
5-1	Releases to the Environment from Facilities that Manufacture or Process Styrene	79
5-2	Samples of Styrene Concentrations in Representative Air in the United States	86
6-1	Analytical Methods for Determining Styrene in Biological Materials	92
6-2	Analytical Methods for Determining Styrene in Environmental Samples	94
7-1	Regulations and Guidelines Applicable to Styrene	100